Skip to main content

Catalyst Pharmaceuticals

Catalyst Pharmaceuticals Inc is an American commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare neuromuscular and neurological diseases. The company commercializes prescription drugs including Firdapse for Lambert-Eaton myasthenic syndrome, Fycompa for epilepsy, and Agamree for Duchenne muscular dystrophy. Main revenue drivers consist of commercial drug sales of Firdapse, Fycompa, and Agamree to specialty pharmacies and healthcare distributors. Catalyst Pharmaceuticals serves neuromuscular specialists, pediatric neurologists, rare disease centers, and rare disease patients across the United States. The company holds a prominent market position as a specialized biopharmaceutical provider for ultra-rare neuromuscular disorders. Headquartered in Coral Gables, Florida, Catalyst Pharmaceuticals Inc is listed on the Nasdaq Stock Market.

4 of the funds FundTelligence covers report a position in Catalyst Pharmaceuticals.

Sector
Health Care
Country
United States
Funds holding it
4

Funds holding Catalyst Pharmaceuticals

Loading...